Search Result
Results for "
prostanoids
" in MedChemExpress (MCE) Product Catalog:
5
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-130223
-
11β-Dinoprostone; 11β-PGE2
|
Prostaglandin Receptor
|
Endocrinology
|
11β-Prostaglandin E2 (11β-Dinoprostone), a Prostanoid derivative, inhibits [ 3H]PGE2 binding to hypothalamic membranes in the rat with a Ki of 53.3 nM .
|
-
-
- HY-19849
-
PGN 1531 free base
|
Prostaglandin Receptor
|
Neurological Disease
|
BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP4 receptor antagonist, with a pKB of 7.6. BGC-20-1531 free base has the potential for the research of migraine headache .
|
-
-
- HY-113756A
-
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
Latanoprost acid, an analog of prostaglandin (PG) F2α, is an selective prostanoid receptor (FP) agonist that specifically activates the FP-PG receptor . Latanoprost acid inhibits RANKL-induced osteoclastgenesis and function by inhibiting ERK, AKT, JNK, and p38 cascade, following by the c-fos/NFATc1 pathway. Latanoprost acid is a medication which works to lower pressure inside the eyes .
|
-
-
- HY-B0131
-
Alprostadil; PGE1
|
Prostaglandin Receptor
Endogenous Metabolite
|
Cardiovascular Disease
Endocrinology
Cancer
|
Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases .
|
-
-
- HY-110351
-
PGN 1531 hydrochloride
|
Prostaglandin Receptor
|
Neurological Disease
|
BGC 20-1531 (PGN 1531) hydrochloride is a potent and selective prostanoid EP4 receptor antagonist, with a pKb of 7.6. BGC 20-1531 hydrochloride has the potential for the research of migraine headache .
|
-
-
- HY-130226
-
-
-
- HY-113096
-
PGD1
|
Endogenous Metabolite
|
Metabolic Disease
|
Prostaglandin D1 is a prostanoid which causes contractile and relaxant on isolated human pial arteries, it is also an inhibitor of ADP-induced platelet aggregation with an IC50 value of 320 ng/ml. Prostaglandin D1 can be used for metabolic research .
|
-
-
- HY-113350
-
TXA2
|
Prostaglandin Receptor
Endogenous Metabolite
|
Inflammation/Immunology
Endocrinology
Cancer
|
Thromboxane A2 (TXA2) is a prostanoid mediator produced by the metabolism of Arachidonic acid (HY-109590) through the cyclooxygenase pathway. Thromboxane A2 activates the thromboxane-prostanoid (TP) receptors. Thromboxane A2 is a potent vasoconstrictor eicosanoid. Thromboxane A2 (TXA2) leads to potent vasoconstriction by stimulation of smooth muscle cells. Thromboxane A2 acts as s tonic immunoregulator to regulate adaptive immune responses .
|
-
-
- HY-113756AR
-
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
Latanoprost acid (Standard) is the analytical standard of Latanoprost acid. This product is intended for research and analytical applications. Latanoprost acid, an analog of prostaglandin (PG) F2α, is an selective prostanoid receptor (FP) agonist that specifically activates the FP-PG receptor . Latanoprost acid inhibits RANKL-induced osteoclastgenesis and function by inhibiting ERK, AKT, JNK, and p38 cascade, following by the c-fos/NFATc1 pathway. Latanoprost acid is a medication which works to lower pressure inside the eyes .
|
-
-
- HY-B0131R
-
Alprostadil(Standard); PGE1 (Standard)
|
Prostaglandin Receptor
Endogenous Metabolite
|
Cardiovascular Disease
Endocrinology
Cancer
|
Prostaglandin E1 (Standard) is the analytical standard of Prostaglandin E1. This product is intended for research and analytical applications. Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases .
|
-
-
- HY-B0601
-
AFP-172
|
Prostaglandin Receptor
Drug Metabolite
|
Cardiovascular Disease
Neurological Disease
Endocrinology
|
Tafluprost acid (AFP-172), an active metabolic form of Tafluprost, is a selective prostanoid FP receptor agonist. Tafluprost acid shows a high affinity for human prostanoid FP receptor with Ki and EC50 values of 0.4 nM and 0.53 nM, respectively. Tafluprost acid has 126 times weaker binding affinity for prostanoid EP3 receptor (IC50=67 nM) than for the prostanoid FP receptor. Tafluprost acid can be used in the research of glaucoma .
|
-
-
- HY-16963
-
-
-
- HY-101987
-
-
-
- HY-108972
-
-
-
- HY-127162
-
PGK1
|
Prostaglandin Receptor
|
Others
|
Prostaglandin K1 (compound 46) is a structurally modified analog of prostacyclin (prostanoid) with an EC50 of 2800 nM for EP1 and a Ki of 2800 nM .
|
-
-
- HY-120665
-
-
-
- HY-163091
-
-
-
- HY-125946
-
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
Latanoprost lactone diol is an intermediate in the synthesis of Latanoprost. Latanoprost is a prostaglandin F2α analogue and an agonist for the FP prostanoid receptor, and lowers intraocular-pressure (IOP) .
|
-
-
- HY-B0577S
-
PHXA41-d4
|
Prostaglandin Receptor
|
Others
|
Latanoprost-d4 is the deuterium labeled Latanoprost. Latanoprost (PHXA41) is a prostaglandin F2α analogue and an agonist for the FP prostanoid receptor, and lowers intraocular-pressure (IOP).
|
-
-
- HY-10794
-
-
-
- HY-119410
-
HN11500
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
Linotroban (HN11500), a Sulotroban (HY-158332) derivative, is an orally active, potent non-prostanoid thromboxane receptor antagonist (TXRA) with a strong antiplatelet profile. Linotroban is used as antithrombotic agent .
|
-
-
- HY-16751
-
-
-
- HY-14839A
-
-
-
- HY-B0577R
-
PHXA41 (Standard)
|
Prostaglandin Receptor
|
Others
|
Latanoprost (Standard) is the analytical standard of Latanoprost. This product is intended for research and analytical applications. Latanoprost (PHXA41) is a prostaglandin F2α analogue and an agonist for the FP prostanoid receptor, and lowers intraocular-pressure (IOP).
|
-
-
- HY-19864
-
AGN 210937
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
Aganepag is a potent Prostanoid EP2 receptor agonist, with an EC50 of 0.19 nM, and shows no activity at EP4 receptor. Aganepag can be used in the research of wound healing, scar reduction, scar prevention and wrinkle treatment and prevention.
|
-
-
- HY-14839
-
-
-
- HY-129922
-
|
Prostaglandin Receptor
|
Endocrinology
|
Prostaglandin I2 is an unstable prostanoid which, through the ‘I prostanoid’ (IP) receptor, inhibits platelet aggregation and promotes vasodilatation in pulmonary vascular beds. AFP 07 is a 7,7-difluoroprostacyclin derivative that acts as a selective and highly potent agonist for the IP receptor (Ki=0.561 nM).1 AFP 07 shows weaker affinity for EP receptors, with Ki values > 100 nM for EP1-3 and > 10 nM for EP4. 16(R)-AFP 07 is an epimer of AFP 07. Its biological properties, particularly through the IP and EP receptors, remain to be evaluated.
|
-
-
- HY-17642
-
UR-7276
|
Prostaglandin Receptor
|
Endocrinology
|
Omidenepag (UR-7276), a pharmacologically active form of Omidenepag Isopropyl, is a selective, non-prostanoid EP2 receptor agonist, with an EC50 of 1.1 nM. Omidenepag shows binding affinities (IC50) 10 nM for h-EP2 .
|
-
-
- HY-153935
-
-
-
- HY-15274
-
CM9; GW671021
|
Prostaglandin Receptor
|
Cancer
|
L-798106 is potent and highly selective prostanoid EP3 receptor antagonist (Ki=0.3 nM), it also has ?micromolar activities at the EP4, EP1 and EP2 receptors with Ki values of 916 nM, >5000 nM and >5000 nM, respectively .
|
-
-
- HY-106699
-
CG 4203 sodium
|
Prostaglandin Receptor
nAChR
|
Cardiovascular Disease
|
Taprostene sodium is a partial agonist at prostanoid prostacyclin (IP) receptors. Taprostene sodium interacts additively with Prostaglandin E2 (PGE2) (HY-101952), ONO-AE1-259 (selective EP2 agonist), and acetylcholine. Taprostene sodium exerts a significant cardioprotection .
|
-
-
- HY-119163
-
-
-
- HY-108565
-
|
Adenylate Cyclase
Prostaglandin Receptor
|
Cardiovascular Disease
|
BMY 45778 is a non-prostanoid prostacyclin mimetic. BMY 45778 inhibits human (IC50 = 35 nM), rabbit (IC50: 136 nM) and rat (IC50 : 1.3 μM) platelet aggregation. BMY 45778 also activates adenylyl cyclase. BMY 45778 is a partial agonist at the prostacyclin receptor .
|
-
-
- HY-115462
-
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
PGN-9856 is a selective and high affinity (pKi ≥ 8.3) ligand at EP2 receptor. PGN-9856 is a potetn and non-prostanoid EP2 receptor agonist (pEC50 ≥ 8.5). PGN-9856 shows anti-inflammatory and anti-glaucoma activities .
|
-
-
- HY-111304
-
-
-
- HY-109163
-
INS-1009
|
Prostaglandin Receptor
|
Inflammation/Immunology
Endocrinology
|
Treprostinil palmitil (TP) is the proagent of DP1 and EP2 agonist, Treprostinil (UT-15), whose EC50 values were 0.6 and 6.2 nM, respectively. Treprostinil palmitil is a pure proagent and possesses no inherent binding to G-protein coupled receptors including prostanoid receptors .
|
-
-
- HY-14973
-
AMG 853
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
Vidupiprant (AMG 853) is a phenylacetic acid derivative. Vidupiprant is a potent and orally active CRTH2 (DP2) and prostanoid D receptor (DP or DP1) dual antagonist with IC50s of 3 nM and 4 nM in buffer, and 8 nM and 35 nM in human plasma, respectively. Vidupiprant has the potential for asthma treatment .
|
-
-
- HY-16635
-
ACT-129968; KYTH-105
|
Prostaglandin Receptor
|
Inflammation/Immunology
Endocrinology
|
Setipiprant (ACT-129968) is an orally active and selective CRTH2 antagonist. Setipiprant interacts with hCRTH2 receptor with an IC50 value of 6 nM. Setipiprant inhibits prostanoid receptors hDP1 and hEP2 with IC50 values of 1290 and 2600 nM, respectively. Setipiprant can be used for the research of asthma and rhinitis .
|
-
-
- HY-129851
-
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
NTP42 is a thromboxane A2 (TXA2) receptor antagonist with an IC50 of 3.278 nM for antagonizing T prostanoid receptor (TP)- mediated [Ca 2+] mobilization following stimulation of cells with the alternative TP agonist U46619 . NTP42 can be used for the treatment of pulmonary arterial hypertension (PAH) .
|
-
-
- HY-110198
-
|
Prostaglandin Receptor
PERK
|
Inflammation/Immunology
|
ONO-8130 is an orally active and selective prostanoid EP1 receptor antagonist. ONO-8130 blocks phosphorylation of ERK in the L6 spinal cord. ONO-8130 relieves bladder pain in mice with cyclophosphamide-induced cystitis. ONO-8130 can be used for interstitial cystitis research .
|
-
-
- HY-19641
-
|
Biochemical Assay Reagents
Prostaglandin Receptor
|
Others
|
AH13205 is a selective prostanoid EP2-receptor agonist. AH13205 causes concentration-related relaxations of Carbachol (HY-B1208)-contracted trachea. AH13205 causes dose-related protection against Histamine (HY-B1204)-induced increases in respiratory rate .
|
-
-
- HY-B0131S2
-
-
-
- HY-10413
-
MK-2894
2 Publications Verification
|
Prostaglandin Receptor
|
Inflammation/Immunology
Endocrinology
|
MK-2894 is a potent, selective, orally active and high affinity (Ki=0.56 nM) full antagonist against E prostanoid receptor 4 (EP4 receptor) (IC50=2.5 nM). MK-2894 possesses potent anti-inflammatory activity in animal models of pain/inflammation and can be used for the research of arthritis .
|
-
-
- HY-10414
-
|
Prostaglandin Receptor
|
Inflammation/Immunology
Endocrinology
|
MK-2894 sodium salt is a potent, selective, orally active and high affinity (Ki=0.56 nM) full antagonist against E prostanoid receptor 4 (EP4 receptor) (IC50=2.5 nM). MK-2894 sodium salt possesses potent anti-inflammatory activity in animal models of pain/inflammation and can be used for the research of arthritis .
|
-
-
- HY-133123
-
|
Prostaglandin Receptor
|
Inflammation/Immunology
Cancer
|
EP4 receptor antagonist 1 is a highly potent and selective competitive prostanoid EP4 receptor antagonist for cancer immunotherapy. EP4 receptor antagonist 1 inhibits human and mouse EP4 receptor with IC50s of 6.1 nM and 16.2 nM, respectively. IC50s >10 μM for human EP1, EP2,and EP3 receptors .
|
-
-
- HY-113096S
-
PGD1-d4
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Metabolic Disease
|
Prostaglandin D1-d4 (PGD1-d4) is deuterium labeled Prostaglandin D1. Prostaglandin D1 is a prostanoid which causes contractile and relaxant on isolated human pial arteries, it is also an inhibitor of ADP-induced platelet aggregation with an IC50 value of 320 ng/ml. Prostaglandin D1 can be used for metabolic research .
|
-
-
- HY-130304
-
iPE2-III
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
8-Isoprostaglandin E2 (iPE2-III) is a member of the isoprostane class of prostanoids. 8-Isoprostaglandin E2 acts at the receptor for thromboxane A2 (the TP) in vivo to induce vasoconstriction and platelet aggregation. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway .
|
-
-
- HY-15342
-
OC000459
|
Prostaglandin Receptor
|
Inflammation/Immunology
Endocrinology
|
Timapiprant (OC000459) is a potent, selective, and orally active D prostanoid receptor 2 (DP2, also known as CRTH2) antagonist. Timapiprant (OC000459) potently displaces [ 3H] PGD2 from human recombinant DP2 (Ki=13 nM), rat recombinant DP2 (Ki=3 nM), and human native DP2 (Ki=4 nM). Timapiprant (OC000459) inhibits mast cell activation of Th2 lymphocytes and eosinophils .
|
-
-
- HY-B0131S
-
|
Prostaglandin Receptor
Endogenous Metabolite
|
Cardiovascular Disease
Endocrinology
|
Prostaglandin E1-d4 is the deuterium labeled Prostaglandin E1. Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases[1][2][3].
|
-
-
- HY-15342A
-
OC000459 sodium
|
Prostaglandin Receptor
|
Inflammation/Immunology
Endocrinology
|
Timapiprant sodium (OC000459 sodium) is a potent, selective, and orally active D prostanoid receptor 2 (DP2, also known as CRTH2) antagonist. Timapiprant sodium (OC000459 sodium) potently displaces [ 3H] PGD2 from human recombinant DP2 (Ki=13 nM), rat recombinant DP2 (Ki=3 nM), and human native DP2 (Ki=4 nM). Timapiprant sodium (OC000459 sodium) inhibits mast cell activation of Th2 lymphocytes and eosinophils .
|
-
- HY-W007888R
-
|
Endogenous Metabolite
|
Metabolic Disease
|
Prostaglandin E1 (Standard) is the analytical standard of Prostaglandin E1. This product is intended for research and analytical applications. Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases .
|
-
- HY-130304S
-
iPE2-III-d4
|
Isotope-Labeled Compounds
Prostaglandin Receptor
|
Cardiovascular Disease
|
8-Isoprostaglandin E2-d4 (iPE2-III-d4) is deuterium labeled 8-Isoprostaglandin E2. 8-Isoprostaglandin E2 (iPE2-III) is a member of the isoprostane class of prostanoids. 8-Isoprostaglandin E2 acts at the receptor for thromboxane A2 (the TP) in vivo to induce vasoconstriction and platelet aggregation. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway .
|
-
- HY-129284
-
|
COX
|
Cancer
|
APHS is a specific and covalent COX-2 inhibitor with neuroprotective effects. COX-2 is a prostaglandin (PG) synthetase overexpressed in colorectal cancer (CRC) and has pleiotropic cancer-promoting effects. APHS modifies COX-2 by acetylating the active site (serine 516), thereby inhibiting prostaglandin production. The neuroprotective activity of APHS is inhibited by prostaglandin E2. APHS also co-inhibits the WNT pathway, an anti-tumor mechanism in addition to COX-2 inhibition .
|
-
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-B0131
-
Alprostadil; PGE1
|
Cardiovascular Disease
Structural Classification
Classification of Application Fields
Ketones, Aldehydes, Acids
Source classification
Endogenous metabolite
Disease Research Fields
|
Prostaglandin Receptor
Endogenous Metabolite
|
Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases .
|
-
-
- HY-113350
-
-
-
- HY-B0131R
-
Alprostadil(Standard); PGE1 (Standard)
|
Cardiovascular Disease
Structural Classification
Classification of Application Fields
Ketones, Aldehydes, Acids
Source classification
Endogenous metabolite
Disease Research Fields
|
Prostaglandin Receptor
Endogenous Metabolite
|
Prostaglandin E1 (Standard) is the analytical standard of Prostaglandin E1. This product is intended for research and analytical applications. Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases .
|
-
-
- HY-120665
-
-
-
- HY-W007888R
-
|
Structural Classification
Monophenols
Ketones, Aldehydes, Acids
Source classification
Phenols
Endogenous metabolite
|
Endogenous Metabolite
|
Prostaglandin E1 (Standard) is the analytical standard of Prostaglandin E1. This product is intended for research and analytical applications. Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases .
|
-
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0577S
-
|
Latanoprost-d4 is the deuterium labeled Latanoprost. Latanoprost (PHXA41) is a prostaglandin F2α analogue and an agonist for the FP prostanoid receptor, and lowers intraocular-pressure (IOP).
|
-
-
- HY-B0131S2
-
|
Prostaglandin E1-d9 is deuterium labeled Prostaglandin E1.Prostaglandin E1 is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inh
|
-
-
- HY-113096S
-
|
Prostaglandin D1-d4 (PGD1-d4) is deuterium labeled Prostaglandin D1. Prostaglandin D1 is a prostanoid which causes contractile and relaxant on isolated human pial arteries, it is also an inhibitor of ADP-induced platelet aggregation with an IC50 value of 320 ng/ml. Prostaglandin D1 can be used for metabolic research .
|
-
-
- HY-B0131S
-
|
Prostaglandin E1-d4 is the deuterium labeled Prostaglandin E1. Prostaglandin E1 (Alprostadil) is a prostanoid receptor ligand, with Kis of 1.1 nM, 2.1 nM, 10 nM, 33 nM and 36 nM for mouse EP3, EP4, EP2, IP and EP1, respectively. Prostaglandin E1 induces vasodilation and inhibits platelet aggregation. Prostaglandin E1 can be used as a vasodilator for the research of peripheral vascular diseases[1][2][3].
|
-
-
- HY-130304S
-
|
8-Isoprostaglandin E2-d4 (iPE2-III-d4) is deuterium labeled 8-Isoprostaglandin E2. 8-Isoprostaglandin E2 (iPE2-III) is a member of the isoprostane class of prostanoids. 8-Isoprostaglandin E2 acts at the receptor for thromboxane A2 (the TP) in vivo to induce vasoconstriction and platelet aggregation. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: